1,227 reports of this reaction
4.3% of all CENEGERMIN BKBJ reports
#4 most reported adverse reaction
OCULAR HYPERAEMIA is the #4 most commonly reported adverse reaction for CENEGERMIN BKBJ, manufactured by Domp farmaceutici S.p.A.. There are 1,227 FDA adverse event reports linking CENEGERMIN BKBJ to OCULAR HYPERAEMIA. This represents approximately 4.3% of all 28,659 adverse event reports for this drug.
Patients taking CENEGERMIN BKBJ who experience ocular hyperaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OCULAR HYPERAEMIA is moderately reported among CENEGERMIN BKBJ users, representing a notable but not dominant share of adverse events.
In addition to ocular hyperaemia, the following adverse reactions have been reported for CENEGERMIN BKBJ:
The following drugs have also been linked to ocular hyperaemia in FDA adverse event reports:
OCULAR HYPERAEMIA has been reported as an adverse event in 1,227 FDA reports for CENEGERMIN BKBJ. This does not prove causation, but indicates an association observed in post-market surveillance data.
OCULAR HYPERAEMIA accounts for approximately 4.3% of all adverse event reports for CENEGERMIN BKBJ, making it a notable side effect.
If you experience ocular hyperaemia while taking CENEGERMIN BKBJ, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.